Fatostatin A

• CAT Number: I001001
• CAS Number: 125256-00-0
• Molecular Formula: C18H18N2S
• Molecular Weight: 294.41
• Purity: ≥95%
• Target: Fatty Acid Synthase (FASN)
• Solubility: DMSO ≥ 27 mg/mL
• Storage: Store at -20°C

Fatostatin A (CAT: I001001) is a small molecule inhibitor that specifically targets the enzyme SREBP (sterol regulatory element-binding protein) cleavage-activating protein (SCAP). SCAP is essential for the activation of SREBP, a key transcription factor involved in the regulation of cholesterol and lipid metabolism. By inhibiting SCAP, Fatostatin A disrupts the processing and nuclear translocation of SREBP, thereby reducing the expression of SREBP target genes involved in cholesterol and fatty acid synthesis. This pharmacological activity makes Fatostatin A a valuable tool in studying lipid metabolism and a potential candidate for the development of therapies targeting dyslipidemia and related metabolic disorders.

Reference

[1]. Li X et al. Fatostatin displays high antitumor activity in prostate cancer by blocking SREBP-regulated metabolic pathways and androgen receptor signaling. Mol Cancer Ther. 2014 Apr;13(4):855-66.

[2]. Shao W et al. Fatostatin blocks ER exit of SCAP but inhibits cell growth in a SCAP-independent manner. J Lipid Res. 2016 Aug;57(8):1564-73.

[3]. Inoue K et al. Fatostatin, an SREBP inhibitor, prevented RANKL-induced bone loss by suppression of osteoclast differentiation. Biochim Biophys Acta. 2015 Nov;1852(11):2432-41.